about
Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRAIdentification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816HDPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia.Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications.Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia.Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection.Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.Oncostatin M is a FIP1L1/PDGFRA-dependent mediator of cytokine production in chronic eosinophilic leukemia.Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects.Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia.What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer?Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.Pharmacologic inhibition of STAT5 in acute myeloid leukemia.
P50
Q28081844-7BA811DF-4A74-4DF3-966E-2D13CD2F4F14Q34048020-1B8E97D9-BCAE-4B56-A3E0-6AAE5EE87849Q35114558-6B512A44-866E-4F4E-80FD-5212F36A4379Q36755221-BA4C305C-3470-43C4-B04B-042183996750Q37611613-5AD38545-F30F-4688-A1BA-46615C5CC687Q38265115-7C3E4F76-C97E-4EAA-8BBF-AE176AD01B9EQ38812117-31CB57A7-3C52-42B8-9DC9-509D9D0E8506Q38866094-E01B7213-5D46-40A5-9498-56419F63F52DQ38998107-EB32ADD9-E0E0-44DD-8477-596A3C93A0FBQ39010730-4011E805-5834-4EF8-9DB8-81DE453CD107Q39089887-CC5877FC-10F9-48B0-9516-2614D3D2F690Q39159911-73B3271F-A000-4C06-A9F7-FCE603212D95Q39795335-7593431C-8165-4121-8236-F7B53F946D23Q42217439-FC27C0C0-8FDE-48B4-9427-91DA03301535Q47653225-A1C9C9C4-9503-475A-80B1-E6AFF503068CQ47694495-3F92C3F1-F9E5-4EAC-8E86-5752E6922901Q48010780-EBFBBFAC-08DF-467D-AE46-3828525E7237Q52689082-A4BE8B55-B67E-48E5-8282-EFF6D2AAE487
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Irina Sadovnik
@ast
Irina Sadovnik
@en
Irina Sadovnik
@es
Irina Sadovnik
@nl
type
label
Irina Sadovnik
@ast
Irina Sadovnik
@en
Irina Sadovnik
@es
Irina Sadovnik
@nl
prefLabel
Irina Sadovnik
@ast
Irina Sadovnik
@en
Irina Sadovnik
@es
Irina Sadovnik
@nl
P106
P31
P496
0000-0001-5418-5942